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Abstract
Surges of COVID-19 have been seen to place large numbers of patients into the ICU.
Establishing standards of care is critical not only for patient care, but to also implement a
baseline of therapy to build upon with future research. COVID-19 produces a hypercoagulable
state resulting in higher occurrences of clotting such as deep vein thrombosis (DVT), and
pulmonary embolism (PE). Anticoagulation medications thin the blood to combat this aspect of
the disease from occurring but does so at the risk of increasing bleeding potential. The purpose
of this study is to evaluate the risk/benefit of anticoagulation usage between ventilated and
non-ventilated COVID-19 ICU patients as both bleeding and clotting are linked to worsened
outcomes. A retrospective analysis reviewed 103 COVID (+) intensive care unit (ICU) patients
with approved standardized COVID anticoagulation from August 2020 through January 2021 at
a small community hospital. Patient data was obtained by navigating through Citrix Visual Apps
including Pharmacy, NextGen EHR, and Paragon Clinician Hub. Pros and cons observed in EHR
navigation were reflected upon in Chapter 5. Primary goal is to compare the endpoint of
thrombotic events along with secondary outcomes of bleeding and overall mortality between
ventilated and non-ventilated patients. Chi-square tests and two-sided t-tests were utilized in
obtaining significance. Significance was defined as p<0.05 and confidence interval of 95%.
This study found ventilated patients experienced significantly more clotting (30 vs 15, p
= 0.0003) in addition to higher bleeding rates (14 vs 5; p = 0.0138) and worse mortality (24 vs
11; p = 0.0016). There were no significant differences with number of prophylactic or
intermediate anticoagulants given between groups. Treatment heparin was used significantly
more in the ventilated group, but this was due to the higher rates of thrombosis being treated.
Apixaban treatment and enoxaparin intermediate dosing resulted in the highest prevalence of
thrombotic events (30.3%, 29.41% prospectively) while heparin treatment accounted for the
highest prevalence of bleeding events (17.39%). Overall, this study displays a potential need for
higher anticoagulation in COVID-19 ICU ventilated patients at the risk of bleeding. Future
studies required include regression analysis on treatment heparin PTT and enoxaparin Xa levels
and associated thrombosis/bleeding events in ventilated patients.
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Definition of Terms and Acronyms
ASA81

Aspirin 81 mg; “Baby Aspirin”

CRP

C-Reactive Protein; COVID-19 inflammatory biomarker

DOAC

Direct-Acting Oral Anticoagulants

DVT

Deep Vein Thrombosis

EHR

Electronic Health Record

HAS-BLED

Bleeding risk score assessment for patients on blood thinning medications for
atrial fibrillation; Hypertension, Abnormal liver/renal function, Stroke history,
Bleeding history, Labile INR, Elderly, Drugs/Alcohol.

HIPAA

Health Insurance Portability and Accountability Act of 1996; patient consent and
patient health information protection

ICU

Intensive Care Unit

IT

Information Technology

LDH

Lactate Dehydrogenase; COVID-19 inflammatory biomarker

LMWH

Low Molecular Weight Heparin

PE

Pulmonary Embolism

PHI

Protected Health Information

PLT

Platelets

PPX

Prophylactic dosing

TX

Treatment dosing

UFH

Unfractionated Heparin
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Intermediate Anticoagulation Dosing in COVID-19 ICU patients:
Evaluation Comparing Ventilated vs Non-Ventilated Populations
Chapter 1: Introduction
The past year and a half has been shaped and defined by the pandemic of COVID-19.
Healthcare around the world tested, and professionals seeking answers to deliver the highest
quality of care possible. Even after over a year of COVID-19, there are still many questions that
need to be confirmed. The nature of COVID-19 increases a patient’s blood to clot. A blood clot
is a mass or clump of blood cells that blocks a blood vessel. The body will naturally make blood
clots as a response to trauma to stop bleeding, but undesired clotting can lead to devastating
outcomes including death. The exact mechanism of how COVID-19 increases coagulability of
blood is not fully confirmed, but the theory is antibodies being produced as part of the immune
response increases clotting activity leading to a higher chance to produce clots (Abou-Ismail,
Diamond, Kapoor, Arafah, & Nayak, 2020). These clots can form in different places in the body
including the lungs (leading to impaired breathing and lung function) and kidneys (impaired
kidney function resulting in accumulation of toxins and drugs).
To help combat this higher coagulable state being produced in hospitalized patients,
anticoagulants are prescribed. Anticoagulants are a class of medications that reduce the ability
of the blood to coagulate and form a clot. Even in those without COVID-19, Chest Guidelines
support anticoagulation in hospitalized patients with increased risk of thrombosis such as
reduced mobility or history of VTE (Kahn, et al., 2012).
Typically seen medications include Unfractionated Heparin (UFH), Low Molecular
Weight Heparins (LMWHs) such as Enoxaparin, and Direct-Acting Oral Anticoagulants (DOACs)
such as Eliquis and Xarelto. The dosing of these are divided into prophylactic dosing and
treatment dosing. Prophylactic dosing means the medication is given at a lower dose to help
prevent a clot from forming. Treatment doses of anticoagulants are used in patients who have
experienced a clot. Whether creating order sets, guidelines, or verifying prescriptions, it is
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important to comprehend the differences in dosing as anticoagulants have different dosing
based on desired effect and indication.
The American Thoracic Society (ATS) and American College of Chest Physicians first
published guidelines regarding prevention of VTE in patients with COVID-19 in June 2020.
Optimal strategies were noted to be sparse with little evidence-based guidelines in the COVID19 population. Nonetheless, the expert panel suggested anticoagulant thromboprophylaxis
over no anticoagulant. In critically ill population, low molecular weight heparins (LMWHs) were
suggested over unfractionated heparin (UFH) in patients with CrCl > 30 mL/min. The reasoning
behind this was to limit staff exposure as opposed to drug-disease correlation; LMWHs require
once or twice a day dosing while UFH is dosed 3 times a day. During the study’s focused
timeline, observational data displayed increased VTE risk in critically ill COVID-19 patients, there
was not clear data regarding further VTE risk. A theorized intermediate dosing (shown in Table
1) was studied at Brigham Health, finding that ICU patients were at a 1.5-2 x higher relative risk
for VTE compared to ward patients (Connors & Levy, 2020). These dosing protocols will be seen
in this study as well, because at the time, this was the most up to date information regarding
VTE prophylaxis. Current guidelines suggest using standard prophylaxis dosing of anticoagulants
for thromboprophylaxis over intermediate or full treatment dosing for all COVID-19 patients.
Table 1: Anticoagulation Dosing Protocol
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Background of the Problem
Because both COVID-19 and critically-ill status increase thrombosis risk, clinicians have
theorized the need for stronger anticoagulation dosing. At the small community hospital
hosting the patient data for this study, an intermediate dosing guideline had been enabled for
the majority of patients admitted to the ICU with COVID-19. As seen in Table 1, the
intermediate dosing is designed to be a Goldilocks regimen between prophylactic and
treatment dosing. As studies continue to be produced, the reviews on intermediate vs
prophylactic dosing is mixed. Some studies have shown mortality benefit while others found no
mortality benefit. Experts and hospital protocols are not standardized to a single guideline or
protocol. Furthermore, guidelines on ventilated patients are not fully established either.
Thrombosis Risk Factors
Although COVID-19 is linked to higher DVT risk, there are baseline factors that need to
be accounted for. Table 2 illustrates risk factors that are associated with an increase in
thrombosis risk. Increasing age has mixed results as a risk factor. The question becomes if older
age is the contributing factor to increasing DVT risk, or if increasing age means more
comorbidities in addition to worsening progression of those comorbidities that influence DVT
risk. Although patients can have many of these additive risk factors, anticoagulation is not
added as a therapy. The exception is for the highlighted section in Table 2; patients who have a
history of DVT/PE, Atrial Fibrillation, or Genetic dispositions are subject to chronic
anticoagulation measures, typically with Direct-Acting Oral Anticoagulants (DOACs). Because of
these additive risks, the study will document and analyze these risk factors to obtain the study
population’s overall baseline.
It would be remiss of this study to not discuss life-saving counseling points regarding
clotting. For those that are experiencing a clot, the symptoms experienced alter based on
location. If a clot forms in the legs or arms (DVT), the area around the clot will be painful, warm
to touch, and begin to swell. If the clot forms in the lungs, also known as a pulmonary
embolism, the patient will experience difficulty in breathing along with chest pain. Pulmonary
embolisms elute similar symptoms compared to COVID-19. This is why imaging is important to
help differentiate the two diagnoses. Lastly, if a clot forms in the brain (stroke), the patient will
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complain of the worst headache they have ever had, impaired speech, and drooping of one side
of the face. It is important as healthcare providers to education patients on these signs and
symptoms so that treatment can be provided as quickly as possible. Knowing the signs and
symptoms clotting in patients also assist health professionals including IT to detect this
dangerous event when analyzing patient histories.
Table 2: Risk factors with known association to thrombosis

Bleeding Risk Factors
All this discussion about the dangers of thrombosis and its association with COVID, why
not just give anticoagulants to everyone? Although a patient may have multiple factors that
were discussed above to be treated for DVT prophylaxis, the risk of suffering a bleed may
outweigh the benefit. Evaluating bleeding risk becomes highly important when discussing
anticoagulation treatment for a patient. There are multiple scoring calculators that can be
utilized to evaluate bleeding risk including HAS-BLED. The factors which HAS-BLED accounts for
includes: age >65, hypertension, renal disease, liver disease, stroke history, previous history of
bleeding, labile INR, additive medications (see Table 3), and excessive alcohol usage. Each point
increases the patient’s risk for bleeding. A score of 3+ means the patient is at high risk of
bleeding and may require alternatives to anticoagulation (Kooiman, et al., 2015).
Evaluation of bleeding determines the concerned adverse effect of anticoagulation.
Because anticoagulation is thinning the blood, the patient becomes more susceptible to
bleeding. Clinically important bleeding is associated with higher mortality and longer ICU stay
(4-8 days) for those on the ventilator for > 48 hours (Cook, et al., 2001). The purpose of thinning
the blood is to reduce the likelihood of a DVT/PE.
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Table 3: Charted medications with known additive bleeding risk

Bleeding can also arise during or after thrombosis treatment. This is due to the stronger
dosing utilized for treatment. Higher doses of anticoagulants will increase the bleeding risk
even further. One example of this occurrence is a patient develops a DVT in one of the legs.
Heparin drip is initiated to treat the DVT. After a couple days, the patient develops dark stools
and is experiencing a gastric bleed. These situations are challenging to manage and are typically
handled on a case-by-case basis. Nonetheless, gathering insight on how often this occurs may
propose future studies in this area along with other precipitating factors that impact
anticoagulation management.
COVID-19 Biomarkers
There are certain irregularities that continuously appear in COVID-19 patients. These
include elevated lab values of CRP, LDH, Ferritin, D-Dimer, and Fibrinogen. Increases in CRP, DDimer, and LDH were associated with worse outcomes and more severe COVID. These
biomarkers can guild the clinician on how severe a patient’s illness is beyond symptomology,
thus were collected to assist in determining severity of COVID19 upon admission along with
ventilation, pressor, and paralytic status.
C-reactive protein (CRP) is a biomarker produced by the liver typically seen with
systemic inflammation. CRP levels in the serum rises rapidly with disease onset, and it plays a
crucial step in part of immune complement activation. Multiple studies on CRP has shown
association with worsening prognosis in COVID-19 patients. European Heart Journal published
an article demonstrated patients with CRP levels higher than the study’s median (10.8 mg/dL)
were significantly associated with VTE (8.3% vs 3.4%), acute-kidney injury (43% vs 28.4%),
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critical illness (47.6% vs 25.9%), and mortality (32.2% vs 17.8%) when compared to patients
with a CRP below the median (Smilowitz, et al., 2021). Based on these results the study will use
10 mg/dL as the comparative cutoff.
Lactate dehydrogenase (LDH) is a protein found in most cells involved with energy
production. LDH is utilized as a biomarker for cell or tissue damage. When damage occurs, LDH
will be released from the cells into the serum, resulting in elevated levels. Elevated LDH for the
purpose of this study is defined as a value above 250 U/L. This reflects the pooled analysis from
the American Journal of Emergency Medicine (Henry, et al., 2020). Their findings of elevated
LDH in association to COVID-19 includes a 6-fold increase in odds of developing severe disease
and a 16-fold increase in odds of mortality.
Another biomarker associated with the inflammatory response is ferritin, a protein that
is used in the body to store iron and protect it from oxidation. Ferritin can be used as a
predictor for cytokine storm as well as progression for critical illness (Lino, et al., 2021). Based
off Lino’s study and cited meta-analysis on hyperferremia, a ROC curve analysis was conducted
finding a cut off value of 1873 ng/mL.
Related to coagulability of COVID-19, D-Dimer and Fibrinogen are often elevated in
patients presenting with COVID-19. D-dimer is a protein that is found after a blood clot
undergoes degradation with fibrinolysis. Elevated values not only are corelated with the patient
potentially experiencing a thrombosis, but also is associated with worse mortality and severity
of illness. The Diabetes & Metabolic Syndrome: Clinical Research & Reviews published an
article showing significantly worse mortality in hospitalized COVID-19 patients with D-Dimer
levels > 2.01 equating a 4-fold increase (Soni, Gopalakrishnan, Vaishya, & Prabu, 2020).
Purpose of the Study
The focus of the study is to retrospectively evaluate the anticoagulation usage amongst
ICU patients with COVID-19. As stated earlier, current guidelines suggest only prophylactic
dosing of anticoagulation. This study will examine outcomes related to intermediate dosing
amongst COVID-19 ICU ventilated and non-ventilated patients. Primary study questions to
evaluate include:
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1) In ICU patients who received anticoagulation, are there significant differences in
primary & secondary outcomes between ventilated and non-ventilated patients?
2) Are there significant differences in COVID-19 admission biomarkers between
ventilated and non-ventilated ICU patients?
3) Are there significant differences between different anticoagulants and associated
primary & secondary outcomes?
These questions concentrate on both the safety and efficacy endpoints of
anticoagulation. Questions related to ventilated vs non-ventilated will potentially distinguish
differences in anticoagulation needs. Question 3 examines efficacy (thrombosis prevention) and
adverse effects (bleeding) between different anticoagulation regimens and medications.
Understanding how to search through healthcare systems and collecting patient data
from EHR is essential in practicing informatics in the healthcare setting as a pharmacist. Due to
the nature of this study, it also serves as a platform to demonstrate learned skills in informatics
coursework through health data collection, proper management of PHI abiding by HIPAA, and
statistical analysis.
Significance of the Study
With the latest surge occurring with COVID-19, understanding drug regimens and
therapies from the previous surge are critical in avoiding mistakes previously made in the
medical community. Now that there is concrete data available with months of patient cases to
analyze, a foundational therapy can be established and/or confirmed for the future. By
reviewing previous literature and comparing to hospital protocols, there can be a discussion on
the risk/benefit of anticoagulation along with differences in dosing (prophylactic vs
intermediate vs treatment).
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Chapter 2: Literature Review
COVID-19 has been highly scrutinized due to the shortcuts made with research and
studies in order to find a treatment to save lives. The first blunder was seen with
Hydroxychloroquine + Azithromycin as a treatment option. As the United States witnessed the
healthcare system strained by COVID-19, with loved ones dying, emotional motivation pushed
incomplete research and trials as temporary standards to give severe covid-19 cases a fighting
chance. Ultimately, the reverse occurred; people were harmed with undesired side effects and
unproven benefits to treating COVID-19. Now that the dust has settled, primary literature is
being conducted more consistently and appropriately. That is why a proper literature review is
required to understand current and updated standards being implemented regarding
anticoagulation.
Method
The approach for this literature review included utilizing the University of Tennessee
database library. The objective was to search for different journal articles that demonstrated
bleeding risks, mortality, and/or benefit in anticoagulation usage not only in COVID-19 ICU
patients, but ICU patients as well. Anticoagulation studies for ICU patients prior to COVID-19
provide a baseline for established guidelines, safety, and dosing. Three databases utilized were:
PubMed, JAMA Network, and Cochrane Library. Terms used in the search engines included
variations of MESH terms such as COVID-19, anticoagulation, ICU, bleeding, ventilated, and
DVT. To account for differences in guidelines while adding validity to the review, search results
were limited to 2 years for COVID-19 while limiting ICU anticoagulation articles to the past 5
years. Combination of MESH terms were utilized to narrow results to less than 100 articles.
From there for each database, articles were chosen from the first 10-20 search results that
yielded the highest relevancy to the study. Articles selected also needed to meet the following
inclusion criteria:
1) Articles and studies written in English
2) Studies were conducted in the United States. Meta analysis studies require at least
majority United States with rest still in developed countries
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3) Scientific literature; not opinion-based, blogs, editorials
Table 4 outlines the articles reviewed. One additional article was included for review that was
not randomized. The study “HOPE-COVID19” revealed mortality benefits for ventilated and
respiratory failure patients, but not hospitalized and noninvasive ventilation patients (Santoro, et
al., 2021). HOPE-COVID19 stood out as the closest and most recent evidence published regarding
ICU ventilated patients.
Findings
Based on the results of the literature review, 3 articles included comparisons of prophylactic
dosing vs intermediate or treatment dosing. These studies did not support the need for
intermediate dosing as mortality benefit was not documented at the risk of having increased
bleeding potential. The rates of thrombosis in the setting of COVID-19 did show increased
thrombosis rates as well as elevated D-Dimer values. Older age and obesity was associated with
worse outcomes. DVT and thrombosis rates varied greatly between institutions. Bleeding
occurrences varied and occurred less, with the highest being 11%. The presence of meta-analysis on
risk factors and associations with COVID were plentiful, but direct head-to-head studies on
therapeutic agents were still being investigated. The standard of care for COVID-19 continues to
evolve, which makes these types of trials hard to conduct or remain relevant to account for current
standards.
Conclusion
The supporting evidence for the use of prophylactic dosing over intermediate matched current
ATS thrombosis guidelines. The need for future head-to-head studies are needed to create a
consistent care plan for the critically ill with COVID-19. Hasan et al. highlighted the need for
individualized care as opposed to set guidelines and strict order sets. Considering how often
guidance in COVID-19 patient care is changing, along with the need for individualized care,
informatic pharmacists should promote order sets for physicians that are more rigorously updated
than established treatments and provided the freedom to choose multiple different medications.
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Chapter 3: Methods
This study was approved by the small community hospital’s Institutional Board Review (IRB)
under Exempt Review as no patient identifiers were used and minimal harm was possible to patients
whose information was collected from the study. Compliance with HIPAA and respecting patient
privacy is of upmost importance when conducting this study. All information that is collected will be
deleted and/or shredded. All patient identifiers excluded from data collection.
Research Design
The study is constructed as a retrospective analysis. The base population of the study is based
around patients who were admitted to the ICU and diagnosed with COVID-19 during the period of
August 1st, 2020 through January 31st, 2021. Timeframe includes the largest peak of concurrent
COVID-19 patients experienced at the hospital in December 2020; that record has since been lapsed
in August 2021. Starting the study in August 2020 also gives enough time since the beginning of the
COVID-19 pandemic to have established standards of care. Early months included mixed and poor
science literature nationwide including the use of hydroxychloroquine + azithromycin in addition to
inconsistent anticoagulation usage.
The patient list was generated by obtaining patents who had an active CPOE order set approved
for COVID anticoagulation. Because COVID(+) patients outside the ICU were also receiving
anticoagulation, the patient list was separated into intensive care and floor. For a brief moment in
December, the ICU was expanded to a few select floor rooms to accompany the surge demand.
These patients were handpicked and included. A total of 103 patients were selected to be analyzed.
All data collected was put into an Excel sheet on an internal drive on the hospital network to ensure
information security.
The primary health applications from Citrix Visual Apps include: Pharmacy, NextGen EHR, and
Paragon Clinician Hub. Each application served as a means to obtain specific information. The
Pharmacy application provided all medication orders along with times administered. This offered
the most accurate illustration of when anticoagulants were started, switched, and/or discontinued
along with noting additive bleeding risk medications. NextGen accesses the outpatient EHR. Not
every patient has been previous admitted to the hospital. If the patient had previously visited the
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same healthcare network, their documents would be viewable including their social history, ongoing
treatments, home medications, and previous diagnoses. Lastly Paragon Clinician Hub contains all the
in-patient documents, medical records, and lab values. Admission lab values assessed COVID-19
biomarkers and severity of illness. Imaging reports confirmed thrombosis events experienced by
patients. The “Documents” tab contained the patient’s hospital course including Critical Care
progress notes. Each application has their strengths, and collectively serve to better enhance the
providers care of the patient.
The excel sheet database was constructed to include mostly binary answers. Answering “No” to
a question or topic would receive the input of “0”, and as expected, answering “Yes” would result in
a “1” being placed. Using 0/1 binary language allows for consistency, quicker input, and less error
prone with analysis. If “Yes / No” were to be used, a spelling error could occur or perhaps a
capitalization difference resulting in left out information (yes/YES would not register if the function
line included =”Yes”). A legend was created for excel sheets “Anticoag_Meds_Before_Bleed” and
“Anticoag_Meds_Before_Thrombosis” to continue a number system and avoid potential spelling
errors. Anticoagulants and associated dosing were assigned different single digit numbers for input;
zero was added if the patient did have previous anticoagulation. Reasons for not having
anticoagulation on board include: active bleeding, pending surgery, severe thrombocytopenia
(<50,000 platelets), or newly admitted patient with no home anticoagulant. Patients who were
diagnosed with a thrombosis with 48 hours along with positive thrombosis imaging had their
anticoagulation status reflect their anticoagulation status at home. Although most patients are not
therapeutically anticoagulated at home, there are those could be anticoagulated prior to visiting the
hospital with Apixaban or Xarelto due to history of atrial fibrillation, history of pulmonary
embolism/deep vein thrombosis, or genetic predispositions.
Rstudio was utilized for analyzing data. Significance was determined by p < 0.05 with a
confidence interval of 95%. Two-sided t-tests and chi square tests are the backbone of determining
significance for this study. T-tests were selected for data that included independent, continuous,
and normal data with little skew between two groups. The groups commonly being compared were
ventilated and non-ventilated. Chi square tests were conducted when comparing the two
independent groups that utilized nominal data (binary, yes/no).

Running Head: INTERMEDIATE ANTICOAGULATION IN COVID-19 ICU PATIENTS

19

Chapter 4: Results
Among the 103 patients, 47 required to be mechanically ventilated during their stay while 56
did not require mechanical ventilation. Table 5 displays demographic and admission laboratory
values pertinent to COVID-19 biomarkers differences between these two groups. Age and sex is not
significantly different. 96.4% of the population is white. Length of stay was significantly higher in the
ventilated population (20.49 vs 12.59 days; p = 0.0031). For admission labs, only elevated LDH was
significantly higher in the ventilated group (37 vs 27; p = 0.0094).
Table 5: Population Demographics and Admission Laboratory Values

Comparison of thrombotic and bleeding risk factors between ventilated and non-ventilated
patients are illustrated in Table 6. These factors were previously discussed in their association to
increase risk of having a thrombotic or bleeding event. Overall, most baseline characteristics and

Running Head: INTERMEDIATE ANTICOAGULATION IN COVID-19 ICU PATIENTS

20

past medical history were not significantly different, except smoking was significantly higher in the
non-ventilated group (23 vs 8; p = 0.0149).
Table 6: Thrombosis and Bleeding Risk Factors

The primary endpoint of thrombosis was significantly higher in ventilated patients (30 vs 15; p =
0.0003). Secondary endpoints of bleeding (14 vs 5; p = 0.0138) and mortality (24 vs 11; p = 0.0016)
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were also found to be significantly higher in ventilated patients. Paralytics were utilized in 25/47
(53%) of ventilated patients. Table 7 outlines the differences in anticoagulant agents used between
ventilated and non-ventilated patients. Prophylactic and intermediate anticoagulant dosed
medications did not significantly differ between the two groups. Treatment heparin was used
significantly more in the ventilated group (27 vs 19; p = 0.0284).
Table 7: Endpoint Results and Anticoagulant Medication Usage

Further data was collected regarding differences between anticoagulant medications and
dosing. Figure 1 displays percentages of thrombosis and bleeding events for number of patients who
received that anticoagulation. For example: Apixaban TX was ordered in 33 different patients; a
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thrombosis was developed in 10 patients who were on apixaban tx at the time of diagnosis (10/33 =
30.3%).
Figure 1: Patients Who Experienced Bleeding/Thrombosis While on Specific Anticoagulant

Lastly, there were patients in the study deemed to have no anticoagulation at the time of their
event. 13 patients suffered a thrombosis without prior anticoagulation. Majority of these patients
were admitted within 48 hours and were not taking anticoagulants at home. 1 patient bled with no
active anticoagulation medications.
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Chapter 5: Conclusion
This study confirms many previously seen associations of ventilated patients including higher
length of stay, higher thrombotic risk, and worse associated bleeding. Anticoagulants did not
significantly differ between the two populations outside of treatment heparin (primary treatment
medication for acute thrombosis). Because ventilated patients were experiencing more thrombotic
events, stronger anticoagulation would be utilized to treat.
Prophylactic Enoxaparin resulted in no bleeding and no thrombotic events. This is most likely
contributed to the fact that patients who are originally on the floor are started on a prophylactic
regimen. These people are generally not as sick as they are either progressing to the ICU or are
coming out of the ICU and deescalating anticoagulant therapy. Interestingly enough, treatment
Apixaban dosing had the highest percentage of thrombotic events (30.3%) followed by intermediate
enoxaparin (29.41%), which may lead to the thought of this patient population requiring stronger
anticoagulant measures. However, Figure 1 confirms the risk of higher bleeding rates seen in
treatment dosing as opposed to prophylactic and intermediate dosing. Overall, these trends confirm
the currents thought of increasing anticoagulant may reduce thrombotic events, but in turn may
increase bleeding potential, thus questioning the beneficial effect of the therapeutic change.
This study showed an overall insignificant difference in DVT and Bleeding risk factors. These lack
of differences in baseline past medical history could be contributed providers potentially not being
able to fully assess a thorough patient history. There are patients who came in abruptly with no
outpatient documentation with the patient being admitted straight to the ICU, and under this
situation it can be hard to obtain a complete patient history.
Overall, evidence is present that COVID-19 ICU ventilated patients experienced more
thrombotic events. Logical progression would indicate that ventilated patients would require a
stronger anticoagulation than floor or ICU non-mechanically ventilated patients. Although current
guidelines state against using treatment anticoagulation, this study proposes the need for future
investigations as to specific monitoring of treatment anticoagulant dosing parameters and
associated bleeding thresholds in ICU ventilated patients. Consistent Xa level monitoring with
enoxaparin tx and PTT with heparin tx.

Running Head: INTERMEDIATE ANTICOAGULATION IN COVID-19 ICU PATIENTS

24

Health Informatics Discussion
From an informatics perspective, one major takeaway from navigating EHR databases to obtain
historical information is the need for a universal EHR or improvement to patient history
documentation. Communication between professions and between facilities is still a primary weak
spot in the US healthcare system. At times, patient data record was found to be highly time
consuming to gather as well as points of inconsistency. This is natural as not every patient recollects
their history the same way to providers, patients may not be available to provide accurate histories
(encephalopathy or dementia), and given the current physician and healthcare shortages, extensive
complete histories are not always available. Inefficiencies arise in obtaining and navigating through
patient histories unless a patient consistently sees the same provider (or stays in the same network).
The largest downside outside of the astronomical cost and resource power required to create a
universal EHR between all providers and facilities, patient data most certainly would be at a higher
risk to unauthorized access and more vulnerable to cyber-attacks. Healthcare facilities have
standardized forms for general histories as a patient visits, but possibly an improvement could be a
“Patient History” document that is continuously updated, including all recorded history and
significant care received with time marks. This document would be pinned somewhere that is easily
accessible on a facility’s interface in a relevant area near the documentation section (or pinned as
the first line to the top of the documentation section).
Limitations of Study
Multiple limitations are acknowledged in this study. Because patients were not identified nor
contacted, 30-day follow up mortality was not plausible. The eleven thrombosis risk factors evaluated in
addition to the unmeasurable hypercoagulable state of COVID19 creates variance between cases. Each risk
factor is not equivalent to each other in terms of perceived risk either. For example, a history of hypertension
is not a reason to initiate anticoagulation, but a history of atrial fibrillation does. Patient size was 103 can
contribute to a larger study size, but overall does not carry the weight of large-scale studies with thousands
of participants.
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